SYNOPSIS

Review of “Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection A Systematic Review”

10/25/2021


One-minute summary

- The authors performed a systematic review of persistent symptoms in Coronavirus Disease 2019 (COVID-19) survivors. The systematic review included 57 studies examining the short and long-term persistent postacute sequelae (PASC) of Coronavirus Disease 2019 (COVID-19). The sample size of eligible COVID-19 survivors was 250,351 with a mean age of 54.4 years (standard deviation [SD]: 8.9), 56.0% were male and 79.0% were hospitalized during acute infection.

- The median proportion of COVID-19 survivors experiencing at least 1 PASC at varying times since diagnosis or hospital discharge:
  - 1 month (short-term): 54.0% (interquartile range [IQR]: 45.0–69.0)
  - 2–5 months (intermediate-term): 55.0% (IQR: 34.8–65.5)
  - ≥6 months (long-term): 54.0% (IQR: 31.0–67.0)

- The median frequency of PASC between low- and middle-income countries (56.0%; IQR: 43.5–67.0) and high-income countries (54.6%; IQR: 33.0–68.3) were similar, respectively. Out of the 57 studies, 45 (78.9%) were from high-income countries defined as median gross national income greater than $12,536.

- The most commonly reported symptoms, by symptom group were (only those with a median proportion >20% included here):
  - **Neurological**: difficulty concentrating (23.8%; IQR: 20.4–25.9)
  - **Mental health**: generalized anxiety disorders (29.6%; IQR: 14.0–44.0), sleep disorders (27.0%; IQR: 19.2–30.3) and depression (20.4%; IQR: 19.2–21.5)
  - **Respiratory**: increased oxygen requirement (65.0%; IQR: 39.3–76.1), chest imaging abnormalities (62.2%; IQR: 45.8–76.5), pulmonary diffusion abnormalities (30.3%; IQR:
22.1–38.5), dyspnea (29.7%; IQR: 14.2–37.0) and ground glass opacification (23.1%; IQR: 19.7–43.0)

- **Functional mobility impairment:** general impairment (44.0%; IQR: 23.4–62.6) and mobility decline (20.2%; IQR: 14.9–30.6)
- **General and constitutional:** fatigue or muscle weakness (37.5%; IQR: 25.4–54.5) and general pain (32.4%; IQR: 22.3–38.4)
- **Dermatological:** hair loss (20.8%; IQR: 17.4–23.4)

- The authors concluded that greater than 50% of COVID-19 survivors experienced PASC 6 months after recovery, and that PASC patients could overwhelm health care resources, especially in low- and middle-income countries.

### Additional information

- Studies were included if they had adults and/or children with a previous COVID-19 diagnosis and reported PASC frequencies. PASC was defined as the presence of at least 1 abnormality diagnosed by (1) laboratory investigation, (2) radiologic pathology, or (3) clinical signs and symptoms that were present at least 1 month after COVID-19 diagnosis or after discharge from the hospital.

- **Limitations noted by authors:**
  
  - The authors did not conduct a meta-analysis due to high heterogeneity in the data and reported only medians with interquartile ranges.
  
  - The authors acknowledge that there is no consensus on the definition of PASC, which led to considerable heterogeneity in the data and made it difficult to compare percentages between studies.
  
  - Authors were unable to stratify the risk of PASC by severity of initial illness (e.g., community-based vs. hospitalized vs. required care in an intensive care unit vs. required invasive life-sustaining measures) or by pre-existing comorbidities, patient age, or other factors that may affect an individual patient’s risk of PASC.
  
  - There was also a lack of standard reporting making it difficult to analyze PASC sequelae and not all symptoms were reported at specific time points, which limited analysis of long-term effects.
  
  - In addition, many of the studies were found through manually searching references, which suggests better database indexing is need for PASC studies in order to conduct subsequent studies.

### PHO reviewer’s comments

- As the authors indicated, the lack of a standardized definition of PASC, and using different baseline time point are major limitations. The World Health Organization (WHO) has recently
published a case definition of post COVID-19 condition which will allow a better estimate of the burden of the condition.¹

- In this review, 79% of the studies participants were hospitalized; therefore this can’t be generalized to the overall individuals infected with SARS-CoV2, but rather can be more appropriately reflective of hospitalized patients. In Ontario, as of October 28 2021, only 5% of all COVID-19 infections resulted in hospitalizations.²

- Vaccination might impact (i.e., improve or change) the incidence, the duration or the severity of the post-COVID-19 condition in vaccinated individuals who might get infected in comparison to those who are unvaccinated. Including vaccination status is essential to help interpreting any trends related to this condition.

- The authors do not mention the limitations and caveats associated with systematic reviews. For example, since the authors did not perform a grey literature search, their results might be biased towards a positive result due to publication bias.

- The Ontario Science Table has estimated that between 57,000 to 78,000 Ontarians had or might be presently affected by the post-COVID 19 condition.³

- A group of investigators from five Provinces including Ontario are partnering to conduct the Canadian COVID-19 Prospective Cohort Study (CAN COV) with the objectives to better understand impact and predict both short and long-term outcomes (early to 1-year) in COVID-19 patients (2000 in total: 1000 non-hospitalized and 1000 hospitalized) and their caregivers.

  - Results from this initiative will be helpful for the planning and management of needed health system resources including developing supportive policies to alleviate the burden of this condition.⁴

References


Citation

Disclaimer
This document was developed by Public Health Ontario (PHO). PHO provides scientific and technical advice to Ontario’s government, public health organizations and health care providers. PHO’s work is guided by the current best available evidence at the time of publication. The application and use of this document is the responsibility of the user. PHO assumes no liability resulting from any such application or use. This document may be reproduced without permission for non-commercial purposes only and provided that appropriate credit is given to PHO. No changes and/or modifications may be made to this document without express written permission from PHO.

Public Health Ontario
Public Health Ontario is an agency of the Government of Ontario dedicated to protecting and promoting the health of all Ontarians and reducing inequities in health. Public Health Ontario links public health practitioners, front-line health workers and researchers to the best scientific intelligence and knowledge from around the world.

For more information about PHO, visit publichealthontario.ca.

©Queen’s Printer for Ontario, 2021